title: Phase I dose-escalation study of nimustine in tumor-bearing dogs.
abstract: Nimustine (ACNU) is an alkylating agent of the nitrosourea and can be an antineoplastic agent in dogs. But, there has been no report on its dose-limiting toxicity (DLT) in dogs. This study was a phase I dose-escalation clinical trial to determine the maximum tolerated dose (MTD) and DLT of ACNU in tumor-bearing dogs. The starting dosage was 25 mg/m(2), and subsequent dosages were administered in increments of 5 mg/m(2) in cohort of 3 dogs. Eight dogs were included, the MTD was determined to be 25 mg/m(2), DLT was neutropenia, and the optimal interval was considered to be 21 days. The data herein provide a basis for the subsequent phase II trial of ACNU in dogs.
authors: Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
authors: Masashi
authors: M
authors: Takahashi
authors: Yuko
authors: Y
authors: Goto-Koshino
authors: Kenjiro
authors: K
authors: Fukushima
authors: Hideyuki
authors: H
authors: Kanemoto
authors: Ko
authors: K
authors: Nakashima
authors: Yasuhito
authors: Y
authors: Fujino
authors: Koichi
authors: K
authors: Ohno
authors: Yasuyuki
authors: Y
authors: Endo
authors: Hajime
authors: H
authors: Tsujimoto
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D007564:Japan; D020714:Maximum Tolerated Dose; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D015376:Nimustine / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D015376:Nimustine